Lexology PRO | Turkey | 1 Dec 2023
Turkey’s Competition Authority has launched a sprawling investigation into 19 companies, including AstraZeneca, Johnson & Johnson, Pfizer, GlaxoSmithKline and Panasonic, for allegedly forming no-poach agreements in the pharmaceutical sector.
Van Bael & Bellis | France | 13 Oct 2023
In a judgment dated 30 August 2023, the French Supreme Court rejected an appeal by Sanofi against the award of damages to the Caisse nationale…
Lexology PRO | European Union, Global, United Kingdom, etc. | 15 Nov 2022
Fake “blue tick” Twitter accounts have been impersonating hundreds of brands in the past week, but what are companies’ options for holding Twitter to account?
Grau & Angulo | Spain | 18 Jan 2021
On 27 November 2020 Barcelona Commercial Court Number 1 dismissed the second preliminary injunction request filed by Sanofi against Mylan in relation…
Herbert Smith Freehills LLP | Australia | 29 Apr 2020
Justice Nicholas’ long-awaited decision in Commonwealth v Sanofi is an Australian first. Of the 4 cases in Australia in which the Commonwealth has…
Rothwell, Figg, Ernst & Manbeck, PC | USA | 18 Mar 2019
Over four years ago, in October 2014, Amgen initiated a patent infringement suit against Sanofi and Regeneron regarding biologics for treatment of…
Rothwell, Figg, Ernst & Manbeck, PC | USA | 27 Feb 2019
On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron…
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | USA | 19 Feb 2019
Sanofi-Aventis U.S., LLC et al. V. Immunex Corp., IPR2017-01884 and IPR2017-01879 (P.T.A.B. Feb. 14, 2019) (HULSE, Moore, Obermann); see also denial…
Jenner & Block LLP | USA | 17 Sep 2018
On September 4, 2018, the French pharmaceutical company Sanofi S.A. (Sanofi) agreed to pay the US Securities and Exchange Commission (SEC) more than…
FB Rice | USA | 29 May 2018
Functionally defined genus claims are vulnerable to invalidity based on lack of written description support, particularly where it is difficult to…